For all we know he may have been pushed out the door.After the last CRL he was no longer working on Afrezza and was put in charge of MNKD's oncology program,which was put on hold over a year ago.Money is tight at MannKind,they were paying him a lot of money,and what was he doing to earn it,he wasn't even involved in the last earnings call.

Adrian Bot led the cancer research at MNKD and left for another job last July.MannKind's Oncology Department is not the place to be right now.

http://pymnts.com/news/businesswire-feed/2011/july/11/kite-pharma-appoints-adrian-bot-md-phd-as-chief-scientific-officer-20110711005185/